Australian-based biotechnology company Opthea intends to raise A$10m ($7.63m) in gross proceeds from the rights offering of shares entitling holders to purchase one share for every 14 existing shares in the company.

The offering will involve 10.7 million shares priced at A$0.93 ($0.71) a share.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company has concurrently announced a private placement of shares to raise A$35m ($26.7m) in gross proceeds.

The proceeds are intended to be used for conducting clinical trials and funding research and development (R&D) expenses to support the development of some of its pipeline drugs.

US-based biotechnology company Vical Incorporated and AnGes MG have entered a research agreement.

The two companies will research for a development programme targeting chronic hepatitis B as part of the agreement.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"US-based biotechnology company Vical Incorporated and AnGes MG have entered a research agreement."

Japanese-based biotechnology company AnGes MG will provide funding for the programme in exchange for an option to negotiate exclusive rights to the programme in Japan, while Vical will conduct pre-clinical research related to the programme.

Sentien Biotechnologies has raised $12m in a series A financing round co-led by Boehringer Ingelheim Venture Fund USA (BIVF USA) and BioInnovation Capital.

The proceeds are intended to be used to fund the initial clinical development of its SBI-101 for the treatment of acute kidney injury (AKI).

Based in the US, Sentien Biotechnologies is focused on cellular therapies development.

French biotechnology company Biophytis has raised €15m ($16m) and €3.73m ($3.97m) respectively through a private placement of bonds and shares of its common stock.

The proceeds are intended to fund phase IIb SARA-OBS / SARA-INT clinical study on Sarconeos, the company’s leading product for the treatment of sarcopenia.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact